Entyvio腸特福

Entyvio

vedolizumab

Manufacturer:

Takeda

Distributor:

Zuellig
/
Firma Chun Cheong
Concise Prescribing Info
Contents
Vedolizumab
Indications/Uses
Adult patients w/ moderately to severely active ulcerative colitis or Crohn's disease who have had an inadequate response w/, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-α antagonist.
Dosage/Direction for Use
Ulcerative colitis & Crohn's disease 300 mg IV infusion at 0, 2 & 6 wk & then every 8 wk thereafter. Retreatment: Dosing at every 4 wk may be considered.
Contraindications
Hypersensitivity. Active severe infections eg, TB, sepsis, cytomegalovirus, listeriosis & opportunistic infections eg, progressive multifocal leukoencephalopathy.
Special Precautions
Patients should be observed continuously during each infusion. Discontinue if a severe infusion-related reactions, anaphylactic reaction or other severe reaction occurs. Patients w/ controlled chronic severe infection or a history of recurring severe infections. Screen patients for TB before starting treatment. Increased risk of malignancy. Patients previously treated w/ natalizumab or rituximab. Concomitant w/ biologic immunosuppressants; live oral vaccines. May impair ability to drive or operate machinery. Women of childbearing potential should use adequate contraception. Pregnancy & lactation.
Adverse Reactions
Nasopharyngitis; bronchitis, gastroenteritis, upper resp tract infection, influenza, sinusitis, pharyngitis; headache; paraesthesia; HTN; oropharyngeal pain, nasal congestion, cough; anal abscess & fissure, nausea, dyspepsia, constipation, abdominal distention, flatulence, haemorrhoids; rash, pruritus, eczema, erythema, night sweats, acne; arthralgia; muscle spasms, back pain, muscular weakness, fatigue; pyrexia.
Drug Interactions
Caution w/ concurrent use of live oral vaccines.
ATC Classification
L04AA33 - vedolizumab ; Belongs to the class of selective immunosuppressive agents. Used to induce immunosuppression.
Presentation/Packing
Form
Entyvio powd for infusion 300 mg
Packing/Price
1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in